Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors.
The development of selective antagonists for bradykinin B(2) receptors has greatly advanced research on the role of the kallikrein-kinin system in acute pancreatitis. Kinins released during the course of the inflammatory injury are the major cause of the vascular symptoms, i.e. pancreatic oedema formation and its consequences, such as haemoconcentration, hypovolaemia and hypotension. Kinins are also involved in the accumulation of potentially cytotoxic factors in the pancreatic tissue. However, treatment with B(2) antagonists must begin prior to the formation of pancreatic oedema in order to inhibit or attenuate the vascular effects. Visceral pain as a possible target symptom for treatment with B(2) antagonists at later time points is suggested by the B(2) receptor-mediated activation of nociceptive afferents.
Griesbacher
T
T
Department of Experimental and Clinical Pharmacology, University of Graz, Austria. thomas.griesbacher@kfunigraz.ac.at
D000818:Animals; D065168:Bradykinin Receptor Antagonists; D006801:Humans; D016234:Kallikrein-Kinin System / Q000187:drug effects / Q000502:physiology*; D007610:Kallikreins / Q000037:antagonists & inhibitors*; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy* / Q000503:physiopathology; D043782:Receptor, Bradykinin B2
D065168:Bradykinin Receptor Antagonists; D043782:Receptor, Bradykinin B2; D007610:Kallikreins